The Latest Breaking News on Pharma

J&J's patent on bedaquiline expired, allowing generic manufacturers to supply the drug. J&J has filed secondary patents. Prices are expected to reduce 3-6x, but some countries are excluded from the deal, raising concerns.

A tornado that tore through eastern North Carolina and struck a large Pfizer pharmaceutical plant has damaged its drug storage facility but not its medicine production areas

Concerns of weight loss and Type 1 diabetes are fueling the rise of our choice for this week's option position in shares of Novo Nordisk.

Abbott Laboratories’ sales of COVID-19 tests fell by a whopping 89% during the second quarter of this year compared with the same time last year — a drop that comes as the world attempts to move on from the pandemic.

The future of the medical devices and equipment industry looks buoyant, given rising chronic conditions and the adoption of advanced technology. Given this backdrop, would it be prudent for investors to buy medical stocks, Terumo Corporation (TRUMY), Haemonetics Corp. (HAE), and MiMedx Group (MDXG)? Read more to find out….

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

U.S. hospital drug supplies may be strained further after a tornado ripped open the roof of a Pfizer factory this week

The U.S. Drug Enforcement Administration’s second-in-command has quietly stepped down amid reporting by The Associated Press that he previously consulted for a pharmaceutical distributor sanctioned for a deluge of suspicious painkiller shipments and did similar work for the drugmaker that became the face of the opioid epidemic: Purdue Pharma

The new Bill, to regulate drugs and medical devices, was formulated without input from major stakeholders, device manufacturers claim. They also want a separate law for regulation of their industry.

MSF reiterated its call for Johnson & Johnson to publicly announce that it will not enforce any ‘secondary’ patents for bedaquiline in any country with a high burden of TB, as J&J’s 20-year primary patent on bedaquiline expired on July 18.

The U.S. Food and Drug Administration issued its most serious type of recall for 348,616 Medtronic defibrillators, saying they are at risk for delivering "a reduced-energy shock or not shock at all," which could lead to cardiac arrest for a patient.